Micromedic
Adi Elkeles
adi@nullm-medic.com
+972-54-6402333
Micromedic is a publicly traded company listed on the Tel Aviv Stock Exchange. The Company focuses on the development and commercialization of cancer-related diagnostics, including early detection of disease, genetic risk and optimization of treatment modalities (personalized medicine). The Company’s portfolio includes CellDetect®, a differential staining technology developed by Zetiq; A blood-based test for the early detection of CRC, developed by BioMark; a genetic test for the identification of cancer and osteoporosis patients at risk for developing BRONJ; and a risk-assessment assay for hereditary breast and/or ovarian cancer, developed by BioGen.
Get more BANG for your BUCK at industry events.
Aneeva's Event Optimization Service helps you drive sales and maximize ROI from industry events via pre-set sales meetings with targeted customers.